Why is Pfizer redeeming these notes early?

While the filing doesn't explicitly state the reason, companies typically redeem debt early to refinance at a lower interest rate, improve their capital structure, or if they no longer need the funds raised by the debt. Given the relatively low interest rates prevalent in late 2020, Pfizer might be taking advantage of lower borrowing costs.

What is a "make-whole" redemption price?

A "make-whole" provision in a bond indenture allows the issuer to redeem the bonds before maturity, but requires the issuer to pay bondholders an amount that compensates them for the loss of future interest payments. This amount is typically calculated based on the present value of the remaining payments, discounted at a rate related to prevailing market interest rates plus a specified premium.

What is the impact on Pfizer's financial statements?

Redeeming debt will reduce Pfizer's total debt and interest expenses going forward. The payment of the "make-whole" amount will represent a cash outflow and could be treated as an extraordinary loss or an adjustment to interest expense, depending on accounting standards. This action generally improves the company's leverage ratios.

What is the significance of the redemption date versus the payment date?

The redemption date (November 28, 2020) is the date on which the notes are officially considered redeemed, and interest accrual stops. The payment date (November 30, 2020) is the date when the holders of the notes will actually receive the redemption proceeds, including the principal, accrued interest, and the "make-whole" premium.

PFE 8-K SEC Disclosure — Nov 18, 2020

Summary

Pfizer Inc. (PFE) announced on November 18, 2020, its intention to redeem its outstanding 5.80% Notes due August 12, 2023, and its 1.950% Notes due June 3, 2021. This action involves the full redemption of approximately $342 million of the 2023 Notes and $1.15 billion of the 2021 Notes. The redemption date is set for November 28, 2020, with payment of the applicable "make-whole" redemption prices and accrued interest to be made on November 30, 2020. This move suggests Pfizer is likely taking advantage of favorable market conditions or refinancing its debt at a lower interest rate. Investors should note that the company anticipates paying a "make-whole" premium, which compensates noteholders for early redemption. The cessation of interest accrual on the redemption date is a standard procedure in such debt retirements. This action is a significant financial event that could impact the company's capital structure and future interest expenses.

Key Highlights

1Pfizer Inc. (PFE) is redeeming its 5.80% Notes due August 12, 2023, in full.
2Pfizer Inc. (PFE) is also redeeming its 1.950% Notes due June 3, 2021, in full.
3The total principal amount outstanding to be redeemed is approximately $342 million for the 2023 Notes and $1.15 billion for the 2021 Notes.
4The redemption date for both sets of notes is November 28, 2020.
5Payment of the redemption prices and accrued interest will be made on November 30, 2020.
6The company will pay applicable "make-whole" redemption prices, as defined in the respective indentures.
7Interest on the Notes will cease to accrue on the redemption date (November 28, 2020), provided Pfizer does not default on payment.

PFIZER INC 8-K Report, Corporate Update (Nov 18, 2020)

Summary

Key Highlights

Frequently Asked Questions